Ultromics
A global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD204—306m (Dealroom.co estimates Aug 2021.)
Company register number 10684811
Oxford England (HQ)
Financials
Estimates*
| EUR | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | <1m | 1.1m | <1m |
| % growth | - | - | 70 % | 68 % | 55 % | (27 %) |
| EBITDA | (<1m) | - | - | (12.5m) | (15.3m) | - |
| % EBITDA margin | - | - | - | (1749 %) | (1383 %) | - |
| Profit | (<1m) | - | - | (11.6m) | (14.0m) | - |
| % profit margin | - | - | - | (1629 %) | (1267 %) | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
£2.0m | Seed | ||
* | £10.0m | Series A | |
N/A | Grant | ||
N/A | - | ||
£8.0m | Series A | ||
N/A | Grant | ||
$33.0m | Series B | ||
| Total Funding | AUD91.8m | ||
Related Content
Recent News about Ultromics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.